Longeveron (LGVN) Short term Debt (2021 - 2023)
Longeveron (LGVN) recorded quarterly Short term Debt of $586000.0 in Q3 2023, up 1.38% quarter-over-quarter from $578000.0 in Q2 2023.
Longeveron (LGVN) Short term Debt (2021 - 2023) Analysis & Trends
Longeveron's Short term Debt history runs 3 years deep, the most recent figure standing at $586000.0 for Q3 2023.
- In Q3 2023, Short term Debt changed N/A year-over-year to $586000.0; the TTM figure through Sep 2023 stood at $586000.0 (changed N/A YoY), while the FY2022 annual figure was $564000.0, up 5.03% from the prior year.
- Short term Debt was $586000.0 for Q3 2023 at Longeveron, up from $578000.0 in the prior quarter.
- In the past five years, Short term Debt ranged from a high of $586000.0 in Q3 2023 to a low of $537000.0 in Q4 2021.
- Historically, Short term Debt has averaged $567200.0 across 3 years, with a median of $571000.0 in 2023.
- Biggest YoY gain for Short term Debt was 5.03% in 2022; the steepest drop was 5.03% in 2022.
- A 3-year view of Short term Debt shows it stood at $537000.0 in 2021, then advanced by 5.03% to $564000.0 in 2022, then advanced by 3.9% to $586000.0 in 2023.
- The last three Short term Debt figures came in at $586000.0 (Q3 2023), $578000.0 (Q2 2023), and $571000.0 (Q1 2023), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Longeveron | 20.35 Bn | 20.33 Bn | 264,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2023 | 586,000.00 |
| Jun 30, 2023 | 578,000.00 |
| Mar 31, 2023 | 571,000.00 |
| Dec 31, 2022 | 564,000.00 |
| Dec 31, 2021 | 537,000.00 |